ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates

ARS Pharmaceuticals reported a slight EPS miss of -0.96% and a revenue beat of +9.10% for the quarter ended December 2025. The print is mixed—meaningful top-line upside but near-flat EPS implies margin or one-off pressure—so absent guidance or pipeline updates this is likely to produce an idiosyncratic, short-term stock reaction rather than a broad sector move; monitor upcoming guidance and catalysts for clearer direction.

Analysis

ARS Pharmaceuticals reported a slight EPS miss of -0.96% and a revenue beat of +9.10% for the quarter ended December 2025. The print is mixed—meaningful top-line upside but near-flat EPS implies margin or one-off pressure—so absent guidance or pipeline updates this is likely to produce an idiosyncratic, short-term stock reaction rather than a broad sector move; monitor upcoming guidance and catalysts for clearer direction.